3.06
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt IOVA?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$3.07
Offen:
$3.05
24-Stunden-Volumen:
9.64M
Relative Volume:
1.03
Marktkapitalisierung:
$1.12B
Einnahmen:
$32.77M
Nettoeinkommen (Verlust:
$-440.22M
KGV:
-1.8323
EPS:
-1.67
Netto-Cashflow:
$-400.48M
1W Leistung:
+0.00%
1M Leistung:
-18.18%
6M Leistung:
-69.91%
1J Leistung:
-74.07%
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
Firmenname
Iovance Biotherapeutics Inc
Sektor
Branche
Telefon
(650) 260-7120
Adresse
825 INDUSTRIAL ROAD, SAN CARLOS
Vergleichen Sie IOVA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
IOVA
Iovance Biotherapeutics Inc
|
3.06 | 1.12B | 32.77M | -440.22M | -400.48M | -1.67 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-10-24 | Eingeleitet | UBS | Buy |
2024-07-29 | Herabstufung | Piper Sandler | Overweight → Neutral |
2023-11-20 | Eingeleitet | Goldman | Buy |
2023-09-18 | Bestätigt | Barclays | Overweight |
2023-05-30 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
2023-03-27 | Fortgesetzt | Wells Fargo | Equal Weight |
2023-01-27 | Hochstufung | Piper Sandler | Neutral → Overweight |
2022-12-09 | Herabstufung | Goldman | Buy → Neutral |
2022-10-31 | Eingeleitet | Guggenheim | Neutral |
2022-08-18 | Fortgesetzt | Wells Fargo | Equal Weight |
2022-01-28 | Hochstufung | Stifel | Hold → Buy |
2021-12-07 | Fortgesetzt | Cowen | Outperform |
2021-06-10 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
2021-05-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
2021-05-19 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
2021-05-19 | Herabstufung | Stifel | Buy → Hold |
2021-05-03 | Eingeleitet | Truist | Buy |
2021-04-16 | Eingeleitet | Goldman | Buy |
2021-03-08 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2020-12-15 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2020-10-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
2020-04-22 | Eingeleitet | Mizuho | Buy |
2020-03-04 | Eingeleitet | Barclays | Overweight |
2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
2020-02-26 | Bestätigt | Oppenheimer | Outperform |
2019-12-18 | Eingeleitet | JMP Securities | Mkt Outperform |
2019-10-01 | Eingeleitet | Stifel | Buy |
2019-04-29 | Eingeleitet | Piper Jaffray | Overweight |
2019-02-28 | Bestätigt | Chardan Capital Markets | Buy |
2019-02-07 | Eingeleitet | Robert W. Baird | Outperform |
2018-12-31 | Fortgesetzt | B. Riley FBR | Buy |
2018-07-06 | Bestätigt | Chardan Capital Markets | Buy |
2018-04-10 | Hochstufung | B. Riley FBR, Inc. | Neutral → Buy |
2018-03-13 | Bestätigt | B. Riley FBR, Inc. | Neutral |
2018-02-23 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
2018-01-25 | Bestätigt | H.C. Wainwright | Buy |
2017-11-01 | Bestätigt | B. Riley FBR, Inc. | Buy |
Alle ansehen
Iovance Biotherapeutics Inc Aktie (IOVA) Neueste Nachrichten
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) | IOVA Stock News - GuruFocus
Is Iovance Biotherapeutics (IOVA) the Most Promising Penny Stock According to Analysts? - Yahoo Finance
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire Inc.
11 Most Promising Penny Stocks According to Analysts - Insider Monkey
Is Iovance Biotherapeutics Inc. (NASDAQ:IOVA) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Yahoo Finance
13 Best Biotech Penny Stocks to Buy According to Hedge Funds - Insider Monkey
Barclays Adjusts Iovance Biotherapeutics (IOVA) Price Target Ami - GuruFocus
Is Iovance Biotherapeutics a Millionaire-Maker? - MSN
Barclays cuts Iovance Biotherapeutics target to $5, keeps rating By Investing.com - Investing.com Canada
Iovance Biotherapeutics (IOVA) Eyes Revenue Growth with TIL Ther - GuruFocus
TILs’ Tomorrow Bringing More Cancers Under Immune Control - Genetic Engineering and Biotechnology News
Iovance Biotherapeutics, Inc. (IOVA): Among Stocks Under $10 that Will Triple - Insider Monkey
10 Stocks Under $10 that Will Triple - Insider Monkey
Trading (IOVA) With Integrated Risk Controls - news.stocktradersdaily.com
Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Iovance Biotherapeutics (NasdaqGM:IOVA) Drops 10% Over The Week In Market Correction - Yahoo Finance
Osteosarcoma Market Set for Groundbreaking Expansion by 2032, Forecasts DelveInsight | Aurora Biopharma, BioAtla, Iovance Biotherapeutics, Isofol Medical AB, Bristol-Myers Squibb, Cellestia Biotech - The Globe and Mail
Iovance: Less And Less Likely To Reap Reward From Its Pioneering Work (NASDAQ:IOVA) - Seeking Alpha
Institutional Investors May Adopt Severe Steps After Iovance Biotherapeutics, Inc.'s (NASDAQ:IOVA) Latest 8.3% Drop Adds to a Year Losses - 富途牛牛
Tumor-Infiltrating Lymphocytes Treatment Market Size in 7MM - openPR.com
Uveal Neoplasms Treatment Market Size in 7MM is expected to grow - openPR.com
Cell Therapy Veteran With 16 Successful Launches Joins TScan Leadership - Stock Titan
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access - GlobeNewswire
Top 3 Health Care Stocks That Are Set To Fly This Month - Benzinga
Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) The Top Penny Stock That Will Skyrocket? - Insider Monkey
1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street - AOL.com
Iovance Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4) - MarketScreener
Iovance Expands Team: 308,710 Stock Options Awarded as Growth Accelerates - StockTitan
Iovance: The Company Makes It Hard To Estimate Revenue Growth (NASDAQ:IOVA) - Seeking Alpha
Philly weekly roundup: Iovance Biotherapeutics expands; Jawnt-SpotHero partnership; Mayor's budget address - Technical.ly
Is Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) the Most Oversold Penny Stocks to Buy According to Analysts? - Insider Monkey
Stifel maintains Buy on Iovance Biotherapeutics stock, $18 target By Investing.com - Investing.com Canada
10 Most Oversold Penny Stocks to Buy According to Analysts - Insider Monkey
Iovance at Barclays Conference: Strategic Growth and Expansion - Investing.com
Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up? - MSN
Melanoma Therapeutics Market to Reach $ 8.35 Bn by 2032Key - openPR
Proficio Capital Partners LLC Acquires New Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World
SBI Securities Co. Ltd. Acquires New Stake in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) - Defense World
Why Iovance Biotherapeutics Stock Zoomed More Than 5% Higher Today - AOL
Can Amtagvi Drive IOVA's Return To Glory - RTTNews
IOVA stock touches 52-week low at $3.62 amid market challenges - Investing.com
Iovance Biotherapeutics Inc to Host Earnings Call - ACCESS Newswire
Iovance Biotherapeutics (NASDAQ:IOVA) Given New $19.00 Price Target at The Goldman Sachs Group - MarketBeat
Iovance Biotherapeutics (NASDAQ:IOVA) Shares Down 5.8% After Analyst Downgrade - Defense World
Iovance Biotherapeutics (NasdaqGM:IOVA) Stock Dips 27% Despite Reaffirmed 2025 Earnings Guidance - Yahoo Finance
Iovance Biotherapeutics price target lowered to $30 from $34 at Chardan - Yahoo Finance
Iovance Biotherapeutics (NASDAQ:IOVA) Price Target Cut to $19.00 by Analysts at The Goldman Sachs Group - Defense World
Finanzdaten der Iovance Biotherapeutics Inc-Aktie (IOVA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Iovance Biotherapeutics Inc-Aktie (IOVA) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Bellemin Jean-Marc | Chief Financial Officer |
Mar 03 '25 |
Option Exercise |
0.00 |
58,590 |
0 |
87,938 |
BILINSKY IGOR | Chief Operating Officer |
Mar 03 '25 |
Option Exercise |
0.00 |
62,106 |
0 |
120,880 |
Vogt Frederick G | Interim CEO & General Counsel |
Mar 03 '25 |
Option Exercise |
0.00 |
223,943 |
0 |
445,059 |
Puri Raj K. | Chief Regulatory Officer |
Mar 03 '25 |
Option Exercise |
0.00 |
59,999 |
0 |
215,411 |
GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Mar 03 '25 |
Option Exercise |
0.00 |
62,497 |
0 |
126,383 |
Vogt Frederick G | Interim CEO & General Counsel |
Jan 14 '25 |
Option Exercise |
0.00 |
20,835 |
0 |
231,071 |
GRAF FINCKENSTEIN FRIEDRICH | Chief Medical Officer |
Jan 14 '25 |
Option Exercise |
0.00 |
2,813 |
0 |
65,464 |
BILINSKY IGOR | Chief Operating Officer |
Jan 14 '25 |
Option Exercise |
0.00 |
2,813 |
0 |
60,352 |
Puri Raj K. | Chief Regulatory Officer |
Dec 16 '24 |
Option Exercise |
0.00 |
8,334 |
0 |
159,171 |
Vogt Frederick G | Interim CEO & General Counsel |
Dec 02 '24 |
Option Exercise |
0.00 |
10,417 |
0 |
214,662 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):